Switching from epoetin alpha to darbepoetin alpha in Japanese hemodialysis patients: Dose conversion ratio

Nephron - Clinical Practice

Volumn 111, Issue 2, 2009, Pages

  Hirai, Takayuki ^a   Sugiya, Naoko ^a   Nakashima, Ayumu ^a   Takasugi, Norihisa ^a   Yorioka, Noriaki ^b,c  

^a Hakuai Clinic   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Darbepoetin alpha; Japanese; Renal anemia

Indexed keywords

HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; ERYTHROPOIESIS; FEMALE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RETICULOCYTE COUNT;

AGED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; EPOETIN ALFA; ERYTHROPOIESIS; ERYTHROPOIETIN; FEMALE; HUMANS; JAPAN; MALE; MIDDLE AGED; RENAL DIALYSIS; RETICULOCYTE COUNT;

EID: 57649093885     PISSN: 16602110     EISSN: None     Source Type: Journal    
DOI: 10.1159/000183843     Document Type: Article

References (18)

1. Egrie JC, Browne JK: Development and characterization of novel erythropoiesis stimulating protein (Nesp). Nephrol Dial Transplant 2001;16(suppl 3):3-13.
2. Macdougall IC, Gray SJ, Elston O, Breen C: Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol 1999;10:2392-2395.
3. Locatelli F, Olivares J, Walker R, Wilkie M, Jenkins B, Dewey C, Gray SJ, European/Australian NESP 980202 Study Group: Novel erythropoesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int 2001;60:741-747.
4. Bock HA, Hirt-Minkowski P, Brunisholz M, Keusch G, Rey S, von Albertini B, for the Swiss EFIXNES Trial Investigators: Darbepoetin alpha in lower-than-equimolar dosage maintains haemoglobin level in stable haemodialysis patients converting from epoetin alpha/beta. Nephrol Dial Transplant 2008;23:301-308.
5. Allen R, Nissenson MD, Suzanne K, Swan MD, Jill S, Lindberg MD, Steven D, Soroka MD, Robert Beatey RN, Wang C, Picarello N, McDermott-Vitak A, Maroni BJ: Randomized control trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis 2002;40:110-118.
6. Vanrenterghem Y, Barany P, Mann JF, Kerr PG, Wilson J, Barker NF, Gray SJ, European/ Australian NESP 970200 Study Group: Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patient. Kidney Int 2002;62:2167-2175.
7. Akizawa T, Koshikawa S, Iwasaki M, KRN321 A08 Study Group:Darbepoetin alfa effectively maintains hemoglobin concentration at extended dose intervals relative to intravenous rHuEPO in Japanese dialysis patients. Ther Apher Dial 2007;11:220-226.
8. Nakai S: An overview of dialysis treatment in Japan (as of Dec. 31, 2006). J Jpn Soc Dial Ther 2008;1:1-28.
9. Gejyo F, Saito A, Akizawa T, Akiba T, Sakai T, Suzuki M, Nishi S, Tsubakihara Y, Hirakata H, Bessho M: Japanese Society for Dialysis Therapy Guideline for Renal Anemia in Chronic Hemodialysis Patients. Ther Apher Dial 2004;8:443-459.
10. Go I, Takemoto Y, Tsuchida K, Nakatani T: The effect of ultrapure dialysate on improving renal anemia. Osaka City Med J 2007;53:17-23.
11. Hsu PY, Lin CL, Yu CC, Chien CC, Hsiau TG, Sun TH, Huang LM, Yang CW: Ultrapure dialysate improves iron utilization and erythropoietin response in chronic hemodialysis patients:a prospective cross-over study. J Nephrol 2004;17:693-700.
12. Sato T, Kurosawa A, Kurihara T, Kurosawa T: Preparation of ultrapure dialysate in Japan - clinical usefulness and short-term future. Blood Purif 2004;22(suppl 2):55-59.
13. Schiffl H, Lang SM, Bergner A: Ultrapure dialysate reduces dose of recombinant human erythropoietin. Nephron 1999;83:278-279.
14. Hori K, Tsujimoto Y, Omori H, Taki M, Nakamura S, Shiromizu A, Suga H, Akizawa T, Koshikawa S: Randomized, controlled study of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Jin to Toseki 2007;62:679-691.
15. Gejyo F, Saito A, Akizawa T, Sakai T, Suzuki M, Nishi S, Tsubakihara Y, Hirakata H, Bessho M: Japanese Society for Dialysis Therapy guidelines for renal anemia in chronic hemodialysis patients. Ther Apher Dial 2004;8:443-459.
16. NKF-K/DOQI Clinical Practice Guideline for Anemia of Chronic Kidney Disease: update 2000. Am J Kidney Dis 2001;37(suppl 1): S186-S211.
17. Agarwal R, Vasavada N, Sachs NG, Chase S: Oxidative stress and renal injury with intravenous iron in patients with chronic kidney disease. Kidney Int 2004;65:2279-2289.
18. Otaki Y, Nakanishi T, Hasuike Y, Moriguchi R, Nanami M, Hama Y, Izumi M, Takamitsu Y: Defective regulation of iron transporters leading to iron excess in the polymorphonuclear leukocytes of patients on maintenance hemodialysis. Am J Kidney Dis 2004;43:1030-1039.